3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial | Synapse
March 29, 2018Open Access
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Key Points
Key points are not available for this paper at this time.
Abstract
Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.